What are the risk factors for emboli in adolescents with femur fractures?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk Factors for Emboli in Adolescent Femur Fractures

Adolescents with femur fractures face significant embolic risk from both thromboembolic pulmonary embolism and fat embolism syndrome, with the fracture itself being the primary risk factor, compounded by surgery/trauma, immobilization, infection, central venous lines, and underlying conditions like systemic lupus erythematosus or thrombocytopenia.

Primary Risk Factors

Fracture-Related Factors

  • Femur fracture location and type: Intertrochanteric (50.3%) and femoral neck fractures (43.9%) are the most common sites associated with PE in femur fracture patients 1. Displaced transverse tibial fractures carry a 33% risk of fat embolism syndrome, while femoral fractures have a 75% incidence of FES 2.

  • Timing of embolic events: PE occurs remarkably early—57.1% of cases develop within the first 24 hours after injury and 89.3% within 48 hours 1. Fat embolism syndrome typically manifests within 36 hours of hospitalization 3.

  • Bilateral fractures: Bilateral femoral fractures significantly increase fat embolism risk 3.

Patient and Treatment Factors

  • Immobilization: Present in 38% of pediatric PE cases, making it the most frequently reported risk factor 4.

  • Surgery and trauma: Accounts for 22% of pediatric PE cases 4. Surgical intervention itself is a major risk factor, though early surgical stabilization paradoxically reduces FES incidence compared to conservative management 3, 2.

  • Central venous lines: Present in 23% of pediatric PE cases 4.

  • Infection: Found in 31% of pediatric PE cases 4.

Adolescent-Specific Risk Factors

  • Systemic lupus erythematosus: A major risk factor in adolescent PE patients 5.

  • Thrombocytopenia: Significantly increases PE risk in adolescents 5.

  • Long-term oral glucocorticoid use: Associated with increased PE risk in adolescent patients 5.

  • Hormonal contraception/pregnancy: Accounts for 15% of pediatric PE cases 4.

  • Malignancy: Present in 15% of pediatric PE cases 4.

Clinical Presentation Differences in Adolescents

  • Fever and chest pain: More common in adolescents compared to adults (P < 0.05) 5. Fever occurs in approximately 7% of PE cases overall 6, but appears more frequent in adolescents.

  • Dyspnea: Remains the most common symptom at approximately 80% 6.

  • Pleuritic chest pain: Occurs in 52% of PE cases 6.

Fat Embolism Syndrome Specific Features

  • Hypoxemia: Mean PO2 of 45 mm Hg at presentation 2.

  • Fever: Mean temperature of 39°C (102.2°F) 2.

  • Petechiae: Present in 40% of FES cases 2.

  • Duration: Less than 4 days in 86% of patients 2.

Critical Diagnostic Pitfalls

  • Delayed diagnosis: Mean diagnostic time is 7.8 ± 8.4 days in adolescents, with outpatient presentations having significantly longer delays (9.4 ± 7.5 days) compared to emergency department presentations (<1 day) 5.

  • Misdiagnosis as respiratory tract infection: The most common initial misdiagnosis in adolescent PE patients 5.

  • Low clinical suspicion: PE is seldom considered in adolescent patients by physicians, particularly in outpatient settings 5. However, 88% of adolescent PE cases score moderate-to-high probability on Wells score and 100% on revised Geneva score 5.

Prevention Strategies

  • Early surgical stabilization: Reduces FES incidence, with surgical correction providing greater risk reduction than conservative management 3.

  • Thromboprophylaxis: Low molecular weight heparin or fondaparinux should be employed 4. LMWH has become the main anticoagulant for VTE prevention in children due to convenient administration and predictable pharmacokinetics 4.

  • Mechanical prophylaxis: Thromboembolism stockings or intermittent compression devices should be used intra-operatively 4.

  • Maintaining hydration and normothermia: Essential preventive measures 4.

  • Expedited surgery and early mobilization: Reduces DVT risk 4.

Mortality and Morbidity Context

  • PE mortality without prophylaxis: 10% in femoral neck fracture patients without prevention 7.

  • PE mortality with prophylaxis: Reduced to 2-3.8% with appropriate thromboprophylaxis 7.

  • FES mortality in isolated fractures: 0% in otherwise healthy young patients with isolated femoral or tibial fractures 2. Early PE in femur fracture patients is not fatal when promptly recognized 1.

  • Incidence: PE occurs in 2.2% of femur fracture patients overall 1, with an incidence of 43.6 per 100,000 hospitalized adolescents 5.

References

Research

Timing of pulmonary embolisms in femur fracture patients: Incidence and outcomes.

The journal of trauma and acute care surgery, 2016

Research

Fat emboli syndrome in isolated fractures of the tibia and femur.

Clinical orthopaedics and related research, 1993

Research

Fat embolism due to bilateral femoral fracture: a case report.

International journal of general medicine, 2012

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pulmonary embolism in adolescents.

Chinese medical journal, 2012

Guideline

Pulmonary Embolism Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.